谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

INSIGHT: A Phase 3, Randomized, Open-Label Study of Ripretinib Vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor Previously Treated with Imatinib with KIT Exon 11 + 17/18 Mutations.

John Raymond Zalcberg,Jean-Yves Blay,Ping Chi,Robin Lewis Jones,Cesar Serrano,Neeta Somaiah,William Reichmann,Kam Sprott,Paulina Cox,Matthew L. Sherman,Rodrigo Ruiz-Soto,Michael C. Heinrich,Sebastian Bauer,Suzanne George

Journal of Clinical Oncology（2025）

引用 0|浏览31
关键词
Sunitinib,KIT Mutations
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要